Please ensure Javascript is enabled for purposes of website accessibility

Here's Why Tilray, Inc. Is Soaring Again Today

By Keith Speights - Sep 11, 2018 at 3:26PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The Canadian marijuana grower reported minor news on Tuesday, but there's a bigger story to its continued momentum.

What happened

Shares of Tilray Inc. (TLRY) were 13.7% higher as of 3:10 p.m. EDT on Tuesday. The Canadian marijuana grower announced that it has shipped its Tilray 2:100 cannabidiol (CBD) oil product to the United Kingdom. However, this shipment was to only one epilepsy patient in the U.K. Was this big enough news to move the needle for the stock? Not really.

It seems likely that today's move was primarily a result of continued momentum as institutional investors and retail investors alike scoop up shares of Tilray. The news about the CBD oil shipment to the U.K., while not all that significant, was nonetheless another reminder of the potential for Tilray in the global medical marijuana market. 

Businessman watching chart go up

Image source: Getty Images.

So what

This marks the second consecutive day this week that Tilray has racked up double-digit percentage gains. The stock reached all-time highs last week, but today's big jump set a new record. Tilray's market cap right now is at $9 billion, making it the second-biggest marijuana stock in the world.

Canadian marijuana stocks, in general, have had a nice run since mid-August following the announcement that Constellation Brands invested an additional $4 billion in Canopy Growth. Tilray's gains, however, have far surpassed all of its peers', including Canopy.

Why has Tilray received such a larger boost than others? One likely reason is that the stock trades on a U.S. stock exchange. The three biggest marijuana stock winners of the last few weeks, Tilray, Canopy, and Cronos Group, not so coincidentally, are the only Canadian marijuana stocks trading on U.S. stock exchanges.

Also, while Canopy has already basked in the glory of Constellation selecting it as a cannabis partner and making a huge investment, many investors are eagerly awaiting the next big deal. Diageo is reportedly looking to follow in Constellation's footsteps. Other major alcoholic beverage companies and big tobacco companies might not be too far behind. Tilray would almost certainly be among the top candidates for any of these companies to consider.

Now what

I don't think that Tilray's momentum is sustainable. However, in the short term, it's quite possible that the stock will continue to move higher.

My view is that buying Tilray at its current valuation would be ill-advised. The company has great growth prospects with the Canadian recreational marijuana market opening next month and increasing opportunities globally to export medical cannabis. But I think Tilray's stock has gotten way ahead of its business prospects after the tremendous gains over the last month.  

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Tilray Stock Quote

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/23/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.